Alzheimer’s disease diagnostics involve a combination of clinical assessments, cognitive tests, imaging techniques, and biomarker evaluations to identify the presence and progression of the disease. Early diagnosis typically begins with a detailed medical history and neurological examination, followed by cognitive tests like the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) to evaluate memory, attention, language, and problem-solving skills. Brain imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) help detect brain atrophy, amyloid plaques, or tau tangles, which are key indicators of Alzheimer’s.
In recent years, advancements in biomarker research have significantly improved diagnostic accuracy. Biomarkers detected in cerebrospinal fluid (CSF) or through blood tests can reveal abnormal levels of amyloid beta and tau proteins, which are closely associated with Alzheimer’s pathology. Genetic testing for mutations in genes such as APOE ε4 may also support risk assessment, especially in familial cases. Early and accurate diagnosis is crucial for timely intervention, planning, and potential participation in clinical trials that may offer access to emerging therapies.
Latest Published Reports by Emergen Research:
https://www.emergenresearch.co....m/industry-report/ba
https://www.emergenresearch.co....m/industry-report/un
https://www.emergenresearch.co....m/industry-report/me
https://www.emergenresearch.co....m/industry-report/su
https://www.emergenresearch.co....m/industry-report/po
